/
/
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
This content is Free Access.
1Center for Genetic Medicine,Children’s National Health System, 2Institute for Biomedical Sciences,The George Washington University School of Medicine and Health Sciences, 3Dana-Farber Cancer Institute, 4Department of Neurology,University of California San Francisco, 5DIPG Centre of Expertise Zurich,Universitats-Kinderspital Zurich
Chapters
- 00:04Title
- 00:59Target DNA Detection and Quantification
- 03:19Data Analysis
- 05:00Results: Representative Mutation Analyses in Pre-amplified Plasma and Cerebrospinal Fluid (CSF) Cell Free DNA (cfDNA)
- 06:32Conclusion
Here, we present a protocol to detect tumor somatic mutations in circulating DNA present in patient biological fluids (biofluids). Our droplet digital polymerase chain reaction (dPCR)-based method enables quantification of the tumor mutation allelic frequency (MAF), facilitating a minimally invasive complement to diagnosis and temporal monitoring of tumor response.
